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Pulmonary surfactant protein SP-D opsonises
carbon nanotubes and augments their
phagocytosis and subsequent pro-inﬂammatory
immune response†
Kirsten M. Pondman,‡a,b Basudev Paudyal,‡a,c Robert B. Sim,d Anuvinder Kaur,a
Lubna Kouser,a Anthony G. Tsolaki,a Lucy A. Jones,c Carolina Salvador-Morales,e
Haseeb A. Khan,f Bennie ten Haken,b Gudrun Stenbecka and Uday Kishore*a
Carbon nanotubes (CNTs) are increasingly being developed for use in biomedical applications, including
drug delivery. One of the most promising applications under evaluation is in treating pulmonary diseases
such as tuberculosis. Once inhaled or administered, the nanoparticles are likely to be recognised by innate
immune molecules in the lungs such as hydrophilic pulmonary surfactant proteins. Here, we set out to
examine the interaction between surfactant protein D (SP-D), a key lung pattern recognition molecule and
CNTs, and possible downstream eﬀects on the immune response via macrophages. We show here that a
recombinant form of human SP-D (rhSP-D) bound to oxidised and carboxymethyl cellulose (CMC) coated
CNTs via its C-type lectin domain and enhanced phagocytosis by U937 and THP-1 macrophages/mono-
cytic cell lines, together with an increased pro-inﬂammatory response, suggesting that sequestration of
SP-D by CNTs in the lungs can trigger an unwanted and damaging immune response. We also observed
that functionalised CNTs, opsonised with rhSP-D, continued to activate complement via the classical
pathway, suggesting that C1q, which is the recognition sub-component of the classical pathway, and SP-D
have distinct pattern recognition sites on the CNTs. Consistent with our earlier reports, complement depo-
sition on the rhSP-D opsonised CNTs led to dampening of the pro-inﬂammatory immune response by
THP-1 macrophages, as evident from qPCR, cytokine array and NF-κB nuclear translocation analyses. This
study highlights the importance of understanding the interplay between innate immune humoral factors
including complement in devising nanoparticle based drug delivery strategies.
Introduction
In recent years, carbon nanotubes (CNTs) have been con-
sidered as vehicles for vaccination and drug delivery.1,2
However, being “non-self”, these delivery platforms encounter
the host’s immune system which can alter their intended
translational application. We have recently assessed how the
innate immune system is able to recognise and process these
nanoparticles, with the goal of extrapolating this knowledge
for the development of a new generation of nanothera-
peutics.3,4 One of the anatomical sites of targeted therapy
using nanotherapeutics is the lungs and a number of studies
have examined the challenges in delivering nanoparticles for
treating a number of pulmonary diseases.5,6 Thus, understand-
ing the mechanism and consequences of interaction between
nanoparticles and the pulmonary innate immune system is of
great importance.4
Pulmonary toxicity of CNTs is one of the most discussed
subjects in nanoparticle research. Lam et al. first showed
that single-walled carbon nanotubes (SWNTs) caused dose-
and time-dependent inflammation and fibrosis in mice,7
whilst another study showed minimal inflammation in the
lungs.8 Granulomas were also shown to be induced by CNTs
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with subsequent fibrogenesis, possibly by alveolar macro-
phage-secreted chemokines causing fibroblast proliferation.9
While CNTs can cause respiratory deficiencies in mice,10
interstitial fibrotic lesions without infiltration have been
shown around CNT clusters in rat lungs.9 These variable
in vivo results can be attributed to the variations in CNT
types (multi-, double- and single-walled), diameter and
length, aggregation states, contamination with other
materials, administration method and route, and surface
coating.11 Studies comparing well-dispersed versus aggregated
SWNTs found that poorly dispersed SWNTs formed clumps
of 5 to 20 μm in diameter in the lungs, which triggered gran-
uloma formation, whereas highly dispersed SWNTs that did
not form any clumps and were found free in the tissue, gave
rise to interstitial fibrosis, but no granulomatous lesions.12–14
Similar results were found in the case of MWNTs, where well
dispersed samples were evenly distributed in cells of the
lung parenchyma, to which the tissues responded by intersti-
tial fibrosis of the alveolar wall, but with very limited granu-
loma formation.15
Surfactant proteins (SP) constitute up to 10% of the dry
weight of pulmonary surfactant, with the rest composed of sur-
factant lipids.16 Of the four SPs, SP-B and SP-C are small
hydrophobic peptides, which interact with surfactant lipids
and maintain surfactant homeostasis, whilst SP-A and SP-D
are large hydrophilic proteins, which perform a range of
immunological functions.17 Both SP-A and SP-D can
opsonise pathogens and foreign particles that may be de-
posited deep in the lungs and then interact with the alveolar
macrophages via putative receptors, leading to their uptake
and downstream immune response,17 suggesting that they can
have a critical role to play in the processing of inhaled
nanoparticles.
Oxidized (Ox) double-walled CNTs (DWNTs) bind eﬃcien-
tly with SP-A and SP-D via their homotrimeric C-type lectin
domain or carbohydrate recognition domain (CRD), as shown
by transmission electron microscopy.18,19 Since the physio-
logical concentrations of SP-A and SP-D are relatively low in
lung surfactant, their binding to nanoparticles can poten-
tially cause significant depletion of these proteins, which can
have a detrimental eﬀect on the lung innate immune
defence.19 Coating Ox-CNTs with SP-A results in an increased
uptake of the particles by alveolar macrophages, while no
inflammatory response is evoked, as determined by nitric
oxide levels.20 Adsorption of lung surfactant corona, consist-
ing of SP-A, B and D, enhances the uptake of SWNTs by
RAW murine macrophages.21 Furthermore, pre-coating CNTs
(pristine, oxidised or aminated) with porcine pulmonary sur-
factant stabilizes the suspensions of CNTs, but induces their
clustering inside monocyte derived-macrophages.22 Coating
SP-A as well as phosphatidylserine on CNTs has been shown
to increase the eﬃciency of phagocytosis.23,24 Recently, SP-D
was found to enhance uptake of polystyrene, carbon black
and silica nanoparticles by alveolar macrophages and dendri-
tic cells in mice.25 In murine alveolar macrophages, SP-A was
found to inhibit agglomeration and uptake of amine-modi-
fied polystyrene nanoparticles (A-PS), whilst it promoted
uptake of unmodified polystyrene nanoparticles (U-PS).26
U-PS and A-PS nanoparticles with bound SP-A or SP-D were
found to neutralise influenza A viral cellular infection
in vitro.27
We have recently examined the interaction of CNTs and
other nanoparticles with innate immune humoral factors
including complement. Classical pathway-activating CNTs get
phagocytosed more eﬀectively by macrophages, resulting in a
down-regulation of the pro-inflammatory cytokine response,28
whereas Au–Ni nanowires, which activate complement weakly,
are poorly phagocytosed, with an increased pro-inflammatory
cytokine response by immune cells.4 Surface modifications of
hydrophobic CNTs are of great importance in order for CNTs
to be well-dispersed in aqueous media and this can be
achieved by covalent or non-covalent surface coatings. We dis-
persed pristine multi-walled CNT (MWNTs), covalently by oxi-
dation (Ox-CNT), or non-covalently with carboxymethyl-
cellulose (CMC-CNT), each having carboxyl functional groups.
Soluble complement factors, C1q and factor H, interacted
diﬀerentially with functionalised CNTs and altered the
immune response even without complement activation,
suggesting that the recognition subcomponents of the comp-
lement pathways can recognise charge patterns due to CNT
surface modifications.3,4
In the present study, we set out to examine the interaction of
SP-D with Ox-CNT and CMC-CNT and its subsequent eﬀect on
complement activation, phagocytosis and immune response by
macrophage cell lines.
Methods
Dispersion and functionalization of CNTs
CNTs (diameters 10–20 nm, length 5–20 µm) were purchased
from Arry Nano (Frechen Königsdorf, Germany). Covalent
functionalization or oxidation was achieved by a modified pro-
cedure, as previously described.29 CNTs were dispersed in a
3 : 1 volume ratio mixture of sulphuric acid (H2SO4, 10 M) and
nitric acid (HNO3, 10 M) by water bath sonication for 1 h
(Transsonic t460 water bath sonicator, 85 Watt, 35 kHz),
followed by probe sonication using QSonica sonicator
(30 eﬀective minutes with 50% on–50% oﬀ cycles, amplitude
100%, 25 watts) on ice. For non-covalent functionalization, the
CNTs were dispersed in a 1 mg ml−1 solution of carboxymethyl
cellulose (CMC) (Sigma) in a 1 : 2 mass ratio by probe soni-
cation. Aggregates and clusters were removed by centrifugation
at 8000g. Excess CMC was washed away using a 0.2 µm pore
size polycarbonate track-etched membrane filter (Whatman)
(Fig. 1a). For covalent functionalization, the strongly acidic
mixture was refluxed at 120 °C for 48 h. The oxidised CNTs
(Ox-CNTs) were washed extensively (3 cycle of centrifugation,
11 000g, 30 min) and re-dispersed in water. Amorphous carbon
residues were removed by overnight stirring of the Ox-CNTs in
10 mM NaOH30 and filtration washings with water using a
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0.1 µm pore size polycarbonate track-etched membrane filter
(Whatman) (Fig. 1b).
Production of a recombinant form of truncated lung
surfactant protein D (rhSP-D)
A recombinant form of human lung surfactant protein D
(rhSP-D) composed of eight N-terminal Gly-Xaa-Yaa triplets,
α-helical neck region and the globular CRD region (rhSP-D),
was expressed in E. coli BL21(λDE3) pLysS strain (Invitrogen) at
37 °C as described earlier.31 Briefly, transformants were grown
in 500 ml LB containing ampicillin (100 μg ml−1) and chloram-
phenicol (50 μg ml−1) to an OD600 of 0.6. Protein expression
was then induced with 0.5 mM isopropyl β-D-1-thiogalactopyra-
noside (IPTG) for 3 h, the cells were centrifuged and then
lysed by sonication.32 The sonicate was centrifuged at high
speed (20 000 rpm, 15 min) and the pellet containing rhSP-D
as inclusion bodies was solubilized in 50 ml buﬀer A (50 mM
Tris-HCl pH 7.5 + 100 mM NaCl + 5 mM CaCl2) with 10 mM
β-mercaptoethanol and 8 M urea. The re-solubilized material
was then dialyzed successively against buﬀer A containing 4 M
urea, 2 M urea, 1 M urea and no urea, each for 2 h. The dialy-
sate was further purified on a Q-Sepharose anion exchange
resin (Pharmacia). The peak fractions, which eluted at 400 mM
NaCl, were loaded onto a maltose–agarose column (Sigma) in
buﬀer A + 5 mM CaCl2 and eluted with 5 mM EDTA pH 7.5.
SDS-PAGE was used to examine each step for purity of rhSP-D
(Fig. 2a). For endotoxin removal, 5 ml of polymyxin B agarose
gel (Sigma) was packed in a 20 ml column and washed with
50 ml of 1% sodium deoxycholate and then further rinsed
with 50 ml of autoclaved distilled water to completely remove
sodium deoxycholate. The aﬃnity purified rhSP-D was then
mixed with the gel and left for 3 h at 4 °C on a shaker. The
level of endotoxin (∼4 pg µg−1 of rhSP-D) in the rhSP-D
protein, collected as unbound fraction, was determined using
QCL-1000 Limulus amebocyte lysate system (BioWhittaker,
Walkersville, MD, USA).
Binding of rhSP-D to Ox-CNT and CMC-CNT
rhSP-D was incubated overnight with CMC-CNT or Ox-CNT in
a buﬀer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl
and 5 mM CaCl2. Unbound protein was removed by repeated
centrifugation at 17 000g for 10 min and the CNTs were
re-dispersed. Protein binding was analysed by SDS-PAGE.
A range of protein: CNTs mass ratios was analysed (1 : 2, 1 : 1,
2 : 1, 4 : 1 and 8 : 1). No increase in binding was found above a
2 : 1 ratio; therefore, this ratio was chosen for subsequent
experiments.
Complement consumption assays for the classical pathway
Complement consumption in normal human serum by CNTs
was analysed using a complement hemolytic assay.33 CNT sus-
pensions (100 μl of 100 μg ml−1 stock) in PBS were added to
100 μl of fresh human serum diluted 1 : 1 in dextrose gelatin
veronal buﬀer with Mg2+ and Ca2+ (DGVB++). Zymosan (0.2 mg
in 100 μl PBS; Sigma) served as a positive control, while serum
Fig. 1 High resolution Transmission Electron Microscopy (TEM) of
CNTs. (a) The pristine CMC-CNTs consist of a high number of parallel-
undamaged carbon walls. The external diameter is approximately 22 nm
while the inner diameter is 5 nm. (b) After acid treatment at high temp-
erature, the outer walls of the oxidised CNTs (Ox-CNTs) show a high
number of defects. In addition, the CNTs are shortened in the process
(not shown).
Fig. 2 Binding of rhSP-D to Ox-CNT and CMC-CNT. (a) SDS-PAGE
(12% w/v acrylamide) analysis of recombinant SP-D. Recombinant
human SP-D containing the homotrimeric neck and CRD regions
(rhSP-D) was expressed in E. coli BL21(λDE3) pLysS. 3 h after induction
with 0.4 mM IPTG, rhSP-D accumulated as an over-expressed protein of
∼20 kDa (lane 3) compared to uninduced cells (lane 2) and was found in
inclusion bodies (lane 4). Following denaturation–renaturation in urea,
the aﬃnity-puriﬁed rhSP-D (Lane 5) was made LPS-free prior to use.
Lane 1, protein molecular weight standard. (b) SDS-PAGE (12% w/v
acrylamide) analysis of rhSP-D bound to Ox-CNTs and CMC-CNTs.
CNTs were incubated overnight with rhSP-D in 1 : 2 weight ratio and
washed extensively via centrifugation to remove unbound SP-D. Lane 1:
molecular weight marker; lane 2: rhSP-D coated Ox-CNTs; lane 3:
rhSP-D-coated CMC-CNTs.
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alone was used as a negative control. To avoid possible inter-
ference by the CNTs with the complement assay, the samples
were centrifuged (13 000g, 10 min) after 1 h incubation at
37 °C, removing all CNTs from the sera. The remaining comp-
lement activity of the supernatants of each sample was deter-
mined. The supernatants were serially diluted 2-fold (1/10–1/
5120 in DGVB++) using a 96 microtitre well plate. Then, 100 μl
of each dilution was incubated with 100 μl of antibody (hemo-
lysin)-sensitized sheep erythrocytes (EA) (TCS, Buckingham,
UK), as described previously33 at the concentration of 108 cells
per ml in DGVB++ for 1 h at 37 °C. Although the CNTs were
removed from the sera, control experiments were performed by
incubating the CNTs with EA for 2 h at 37 °C. No hemolysis
was observed in these control experiments. After incubation,
cells were spun down (700g, 10 min, room temperature), and
released hemoglobin in the supernatant was measured at
541 nm. Total hemolysis (100%) was measured by lysing EA
with water. Background spontaneous hemolysis (0%) was
determined by incubating EA with DGVB++ only. Hemolytic
complement (CH50) values, the serum dilution required for
50% cell lysis, were calculated and compared. The experiments
were carried out in triplicate.
Phagocytosis assay
Uptake of CNTs by U937 cells (a monocytic cell line derived
from histiocytic lymphoma) was measured using an ELISA
type assay as previously described.28 First, CMC-CNTs and
Ox-CNTs were biotinylated, as follows: 200 µg CNTs in 1 ml
0.1 M MES buﬀer [2-(N-morpholino)ethanesulfonic acid, pH 5]
were stirred for 2 h with 1 mg pentylamine biotin (Pierce,
Thermo Fisher Scientific) in the presence of 4 µg EDC [1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide]. The reaction was
stopped by adding 50 µl of 0.1 M ethanolamine (Sigma). The
resulting biotin-CMC-CNTs and biotin-Ox-CNTs were dialyzed
extensively against PBS (pH 7.4) in order to remove remaining
reactants and MES.
To confirm the eﬃciency of biotinylation, biotinylated
CNTs were incubated with Alexa Fluor 488-conjugated strepta-
vidin for 30 min and then washed via centrifugation at 17 000g
for 10 min three times and re-dispersed. Dispersed biotiny-
lated CNTs were visualized with a Leica microscope using LAS
software (ESI†).
U937 cells were cultured in complete RPMI 1640 medium
(Gibco) containing 10% fetal calf serum (FCS), 2 mM
L-glutamine, 100 U ml−1 penicillin, 100 µg ml−1 streptomycin
and 1 mM sodium pyruvate, passaged, and then washed in
AIM-VAlbuMAX serum free medium (GIBCO). In each well of a
24 well tissue culture plate, 5 × 105 cells were incubated in
AIM-V AlbuMAX with the above-mentioned supplements (but
no FCS). To each well, 20 µg of biotin-CMC-CNTs or biotin-Ox-
CNTs were added and incubated for 6 h; a negative control was
incubated with PBS only. Cells were harvested and washed five
times in PBS using centrifugation at 300g and stored at −80 °C
until further use. All experiments were performed in duplicate.
For quantification, microtitre wells (NUNC, Polysorb) were
coated with 100 µl Avidin (Pierce) at 50 µg ml−1 in 0.1 M
Na2CO3, pH 9.0 for 1 h at room temperature, followed by
blocking with 1 mg ml−1 horse IgG in PBS for 1 h at room
temperature. The pelleted U937 cells were lysed using 25 µl
lysis buﬀer (10 mM HEPES, 20 mM NaCl, 0.5 mM EDTA,
pH 7.5, 1% Triton X 100), following which 25 µl 0.1 mg ml−1
horse IgG in PBS (as blocking agent) was added. The lysate or
biotinylated CNTs (to generate a standard curve) was incubated
for 1 h at room temperature in the wells. The plate was washed
7 times with 0.1 mg ml−1 horse IgG in PBS and incubated with
1 : 2000 dilution of streptavidin–horseradish peroxidase (HRP)
conjugate (Sigma) for 1 h at room temperature. 3,3′,5,5′-
Tetramethylbenzidine (TMB) (Biolegend, London, UK) was
used as a substrate for the HRP and the yellow product
obtained after stopping the reaction with 2 N H2SO4 was read
at 450 nm in a plate reader (BioRad).
Fluorescence microscopy
Qualitative analysis of biotinylated CMC-CNTs uptake was
carried out using THP-1 cells. For these experiments, 1 × 105
THP-1 cells (per coverslip) were plated on 13 mm glass cover-
slips and treated for 24 h with 100 nM phorbol myristate
acetate (PMA, Sigma) in complete RPMI 1640 contain-
ing 10% v/v FCS, 2 mM L-glutamine, 100 U ml−1 penicillin,
100 µg ml−1 streptomycin and 1 mM sodium pyruvate.
Diﬀerentiated THP-1 cells were washed three times with PBS at
37 °C to remove excess PMA. Biotinylated CMC-CNTs coated
with rhSP-D were incubated for 1 h at 37 °C in normal human
serum in 1 : 1 ratio with DGVB++ buﬀer for complement de-
position. CNTs were washed via centrifugation at 7000g for
10 min three times and re-dispersed via water bath sonication
for 10 min before incubating with THP-1 cells. Cells were
exposed to 4 μg ml−1 biotinylated CMC-CNTs coated with
rhSP-D (rhSP-D + CMC-CNT), biotinylated CMC-CNT coated
with rhSP-D and then complement deposited (rhSP-D + serum
+ CMC-CNT), complement deposited biotinylated CMC-CNTs
(serum + CMC-CNTs) or biotinylated CMC-CNTs alone in
500 µl of serum-free RPMI 1640 medium for 2 h and 4 h. Cells
were washed twice with PBS, fixed with 4% paraformaldehyde
for 10 min, washed and processed for immunofluorescence.
The coverslips were permeabilized using a buﬀer containing
20 mM HEPES–NaOH pH 7.4, 300 mM sucrose, 50 mM NaCl,
3 mM MgCl2, 0.5% Triton X-100 and 10% sodium azide for
5 min on ice. The cells were stained for 30 min with 1.6 μM
Hoechst 33342 (Life technologies) to visualize the nucleus,
2 μg ml−1 Alexa-Fluor546-conjugated wheat germ agglutinin
(Invitrogen) to reveal the plasma membrane, and Alexa Fluor
488-conjugated streptavidin (Biolegend) to reveal biotinylated
CMC-CNTs. Cells were washed twice, mounted using
Citifluor anti-fade (Citifluor, UK), and observed under a
Nikon Eclipse TE2000-S confocal microscope with 60× oil
lens.
To observe nuclear translocation of NF-κB, 1 × 105 THP-1 cells
per 13 mm coverslip were diﬀerentiated with PMA, as described
above, and incubated with 4 μg ml−1 of rhSP-D bound CMC-CNTs
(rhSP-D + CMC-CNT), rhSP-D bound and complement deposited
CMC-CNT (rhSP-D + serum + CMC-CNT), complement deposited
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CMC-CNTs (serum + CMC-CNTs) or CMC-CNTs alone in 500 µl of
serum-free RPMI 1640 medium for 2 h. Following fixation and
permeabilization as described above, the cells were incubated
with rabbit anti-NF-κB p65 polyclonal antibodies (1 : 500, Santa
Cruz Biotech), followed by Alexa Fluor 488-goat anti-rabbit anti-
body (1 : 500, Abcam), and observed with a Leica Fluorescent
microscope using LAS software.
Quantitative RT-PCR analysis
In a 24 well cell culture plate (Nunc), 10 µg of diﬀerent forms
of CNTs as described above, in PBS were added to each well
containing 5 × 105 cell U937 cells in AIM-V AlbuMAX serum
free medium and incubated for 15, 30, 45, 60, 120 or 360 min,
and for 30, 60, 120 or 360 min in the case of diﬀerentiated
THP-1 cells. Control samples included THP-1 or U937 cells
incubated with PBS only for 30 min. Cells were harvested,
spun down (3000g, 5 min), and stored at −80 °C. Total RNA
was extracted from frozen cell pellets using the GenElute
Mammalian Total RNA Purification Kit (Sigma-Aldrich).
Samples were treated with DNase I to remove any contami-
nating DNA. To inactivate DNase I, samples were heated at
70 °C for 10 min, and then kept on ice. A Nano Drop 2000/
2000c spectrophotometer (Thermo-Fisher Scientific) was used
to determine the amount and purity (260/280 nm ratio) of
RNA. The cDNA was synthesized using High Capacity RNA to
cDNA Kit (Applied Biosystems).
Primers (Table 1) were designed using Primer-BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
The qPCR reaction consisted of 5 μl Power SYBR Green
MasterMix (Applied Biosystems), 75 nM forward and reverse
primer, and 500 ng template cDNA in a 10 μl reaction volume.
PCR was performed using a Step One Plus Real-Time PCR
System (Applied Biosystems). After initiation steps of 2 min at
50 °C and 10 min at 95 °C, the template was amplified for 40
cycles, each cycle comprised of 15 s at 95 °C and 1 min at
60 °C. Samples were normalized using the expression of
human 18S rRNA. Data was analyzed using the Step One soft-
ware v2.3 (Applied Biosystems). Ct (cycle threshold) values for
each target gene were calculated. Relative expression of each
target gene was calculated using the Relative Quantification
(RQ) value, using the equation: RQ = 2−ΔΔCt for each cytokine
target gene, and comparing relative expression with that of the
18S rRNA constitutive gene product. Assays were conducted in
triplicate.
Multiplex cytokine array analysis
Secreted cytokines [interleukin (IL)-6, IL-10, IL-12p40,
IL-12p70, IL-1α, IL-1β, tumor necrosis factor (TNF)-α, IL-15,
IL-17A, IL-9, TNF-β, interferon (IFN)-α2], chemokines [mono-
cyte chemoattractant protein (MCP)-3, macrophage-derived
chemokine (MDC), eotaxin, fractalkine, growth regulated onco-
gene (GRO), IL-8, interferon gamma-induced protein (IP)-10,
MCP-1, macrophage inflammatory protein (MIP)-1α, MIP-1β,
monokine induced by gamma interferon (MIG), interferon-
inducible T-cell alpha chemoattractant (I-TAC), monokine
induced by gamma interferon (MIG)], growth factors [IL-9,
IL-2, epidermal growth factor (EGF), fibroblast growth factor
(FGF)-2, granulocyte colony stimulating factor (G-CSF),
granulocyte macrophage (GM)-CSF, IL-3, IL-7, vascular endo-
thelial growth factor (VEGF)], and ligand and receptors [FMA-
like tyrosine kinase 3 ligand (FLT-3L), interleukin 1 receptor
antagonist (IL-1RA), sCD40L] were measured by MagPix
Milliplex kit (EMD Millipore). Briefly, 25 µl of assay buﬀer was
added to each well of a 96-well plate, followed by addition of
25 µl of standard, controls or supernatants of cells (treated
with CNTs). 25 µl of analyte-specific antibody immobilised
beads were added to each well, followed by incubation for 18 h
at 4 °C. After washing the plate with the assay buﬀer, 25 μl of
detection antibodies were incubated with the beads for 1 h at
room temperature. 25 μl of streptavidin–phycoerythrin was
then added and incubated for 30 minutes. Following a
washing step, 150 μl of sheath fluid (BD Biosciences) was
added to each well and the plate was read using the Luminex
Magpix instrument (Bio-Rad).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 6.0 (GraphPad Software). An unpaired 2-side t-test or a
2-way ANOVA was used on the data for any significant diﬀer-
ence in expression. P values were computed and graphs com-
piled and analysed.
Results
rhSP-D binds to Ox-CNT and CMC-CNT stably
Pristine CNTs of 5–20 µm in length and 10–20 nm diameters
were well dispersed by either non-covalent coating with CMC
or covalent functionalisation (oxidation); the dispersions were
found highly stable for months. Transmission Electron
Microscopy (TEM) imaging clearly revealed irregularities in the
structure of the oxidised Ox-CNTs (Fig. 1b) which were not
found on pristine CMC-CNTs (Fig. 1a). The Ox-CNTs were also
significantly shortened (length 100–500 nm) (not shown). The
NaOH treatment removed all amorphous carbon from the
surface of the nanotubes (not shown). After incubation with
rhSP-D and extensive washing, we found that purified rhSP-D
Table 1 Target genes and terminal primers for qPCR analysis (5’-3’)
Targets Forward primer Reverse primer
18S ATGGCCGTTCTTAGTTGGTG CGCTGAGCCAGTCAGTGTAG
IL-1β GGACAAGCTGAGGAAGATGC TCGTTATCCCATGTGTCGAA
IL-6 GAAAGCAGCAAAGAGGCACT TTTCACCAGGCAAGTCTCCT
IL-10 TTACCTGGAGGAGGTGATGC GGCCTTGCTCTTGTTTTCAC
IL-12 AACTTGCAGCTGAAGCCATT GACCTGAACGCAGAATGTCA
TGF-β GTACCTGAACCCGTGTTGCT GTATCGCCAGGAATTGTTGC
TNF-α AGCCCATGTTGTAGCAAACC TGAGGTACAGGCCCTCTGAT
NF-κB GTATTTCAACCACAGATGGCACT AACCTTTGCTGGTCCCACAT
NLRP3 GCCATTCCCTGACCAGACTC GCAGGTAAAGGTGCGTGAGA
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(Fig. 2a) stably bound to both CMC-CNTs and Ox-CNTs, as
evident from SDS-PAGE analysis (Fig. 2b).
Coating of CNTs with recombinant human SP-D enhances
complement consumption
In view of our earlier observation that Ox-CNTs and CMC-CNTs
can activate the complement classical pathway,3,4,28 Ox-CNTs
and CMC-CNTs coated with rhSP-D were investigated for comp-
lement activation via the classical pathway. Both rhSP-D coated
CNTs showed a very significant (p < 0.0001, n = 3) enhancement
(∼2 fold) in complement consumption compared to uncoated
CNTs (Fig. 3). Complement activation, therefore, appears to be
facilitated by rhSP-D coating on CNTs, suggesting that rhSP-D
and C1q do not compete for binding to the same sites on the
CNTs, i.e. rhSP-D does not inhibit C1q binding. Bound rhSP-D
could also enhance complement activation by other mecha-
nisms, e.g. by providing more sites for the covalent binding of
C3b or C4b, thus enhancing formation of the convertase
enzymes, C3bBb and C4b2a, which would increase consump-
tion (activation) of complement. In a previous paper,28 it was
shown that coating DWNT with other proteins, e.g. BSA and
fibrinogen, can also enhance complement consumption, indi-
cating that the eﬀect arises due to the availability of more
C4b/C3b binding sites.
rhSP-D enhances uptake of CNTs by U937 and
THP-1 macrophage cell lines
For the CMC-CNTs, binding of rhSP-D increased cellular
uptake by about 30% (Fig. 4a), similar to previously reported
increase in uptake of CMC-CNTs coated with serum and
C1q.3,4,28 In contrast, there was a 30% decrease in cellular
uptake of rhSP-D bound Ox-CNTs (Fig. 4a); this also fits with a
similar pattern of cellular uptake seen with C1q and factor
H.3,4 These opposing eﬀects in uptake between the two
diﬀerent types of CNTs are intriguing. It is possible that the
Fig. 4 Diﬀerential uptake of CNTs by macrophage-like cell lines after
coating with rhSP-D, and with or without serum treatment (i.e. comp-
lement deposition). (a) Biotinylated CMC-CNTs and biotinylated Ox-CNTs
were incubated with rhSP-D in 1 : 2 w/w ratio (CNT : protein). After removal
of unincorporated rhSP-D, U937 cells were incubated with 20 µg of
rhSP-D bound biotinylated CMC-CNTs or biotinylated CMC-CNTs alone
for 6 h. Following extensive washing in PBS, the cells were lysed and the
amount of internalised CNTs was quantiﬁed by an ELISA type assay as
described.28 All experiments were carried out in triplicate; error bars rep-
resent ±standard deviation; p = 0.0316 for Ox-CNTs and p = 0.053 for
CMC-CNTs. (b) To conﬁrm internalisation of CNTs, confocal microscopy
was used. Diﬀerentiated THP-1 cells were exposed to rhSP-D bound bioti-
nylated CMC-CNTs (rhSP-D + CMC-CNT), rhSP-D bound biotinylated
CMC-CNT plus complement deposition (rhSP-D + serum + CMC-CNT),
complement deposited biotinylated CMC-CNTs (serum + CMC-CNT), or
biotinylated CMC-CNTs alone for 2 h and 4 h. Cells were washed, ﬁxed,
permeabilised and stained with Alexaﬂuor-488 labelled streptavidin to
reveal internalised biotinylated CMC-CNTs. Alexaﬂuor 546-conjugated
wheat germ agglutinin was used to reveal plasma membrane (red) and the
nucleus was stained with Hoechst 33342 (Blue). Images shown are single
sections taken with a Nikon confocal microscope; scale bar 20 μm. Arrows
highlight endocytosed biotinylated CMC-CNTs. (c) Magniﬁed orthogonal
views of the same confocal images demonstrate uptake of biotinylated
CMC-CNTs (green), plasma membrane in red, scale bar 20 μm.
Fig. 3 Complement consumption by rhSP-D coated CNTs. Hemolytic
assay was carried out to determine complement consumption by
rhSP-D coated and uncoated CMC-CNTs and Ox-CNTs. A signiﬁcant
increase in complement consumption by rhSP-D coated CNTs com-
pared to uncoated counterparts was observed. Serum and zymosan
were used as negative and positive control, respectively. All experiments
were carried out in triplicate; error bars represent ±standard deviation. A
2-side unpaired t-test (with Welch’s correction) was performed on the
data to determine signiﬁcant diﬀerences in complement consumption
between each uncoated (control) and coated CNTs. All these compari-
sons were signiﬁcant (p < 0.01).
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mode or density of binding of soluble pattern recognition
receptors to CNTs can alter their ability to interact with their
cognate receptors. There is also a large diﬀerence in length
between the two types of coated CNTs, which may be relevant.
Confocal microscopy using diﬀerentiated THP-1 cells con-
firmed that rhSP-D, like serum treatment of CNTs, enhanced
the uptake of CMC-CNTs (Fig. 4b). Uptake of CMC-CNTs did
not seem to take place at all parts of the cells, as shown in
orthogonal section of the THP-1 cells (Fig. 4c). Interestingly,
complement deposition on rhSP-D coated CMC-CNTs (rhSP-D +
serum) reduced uptake compared to rhSP-D coating alone or
serum treatment alone at both early (2 hours) and late (4 hours)
time points (Fig. 4b). The reduction in uptake of rhSP-D de-
posited CMC-CNTs with additional complement deposition
could be due to steric hindrance or competition for a receptor.
Cytokine and transcription factor mRNA expression by U937
and THP-1 treated with rhSP-D bound CNTs
Cytokine and transcription factor gene expression profiles of
U937 cells were measured at six time-points up to 6 h, follow-
ing treatment with CNTs, with and without rhSP-D coatings.
In U937 cells, mRNA levels for the pro-inflammatory cytokines
(IL-1β, TNF-α and IL-12) were up regulated by Ox-CNTs, when
compared to CMC-CNTs (Fig. 5a). For IL-1β, this observation is
particularly dramatic. The eﬀect of rhSP-D coating on CNTs
was subtle, with a slight up-regulation in mRNA expression by
Ox-CNTs for IL-1β and TNF-α. In the case of IL-12, for
CMC-CNTs coated with rhSP-D, there was a slight down-regu-
lation in mRNA levels. For the anti-inflammatory cytokines,
IL-10 and TGF-β, there was a slight down-regulation of mRNA
Fig. 5 (a) Cytokine gene expression proﬁle of U937 cells challenged with CNTs and rhSP-D bound CNTs. For the measurement of transcripts of
pro- and anti-inﬂammatory cytokines as well as NF-κB and NLRP3, cells were incubated with each CNTs, for the following time points: 15, 30, 45,
60, 120 and 360 minutes (X-axis). In control experiments, cells were incubated with PBS only for 30 minutes. The expression of cytokines was
measured using real-time qPCR and the data normalized to 18S rRNA gene expression as an endogenous control. Assays were conducted in tripli-
cate. Error bars represent ±standard deviation. A 2-way ANOVA was performed on the data to determine signiﬁcant diﬀerences in expression
between each un-coated and coated nanoparticle. All these comparisons were signiﬁcant (p < 0.05), except where shown (ns: not signiﬁcant, p >
0.05). (b) Multiplex cytokine array analysis of the supernatants of U937 cells treated with CNTs and rhSP-D bound CNTs. Secreted cytokines, chemo-
kines and growth factors (IL-8, IL-10, IL-12p40, IL-1α, IL-1β, TNF-α, MIG, I-TAC, MCP-1 and G-CSF) levels were measured by MagPix Milliplex kit
(EMD Millipore). Supernatants were taken after 48 h treatment, except for MCP-1 (12 h). Error bars represent ±standard deviation. A 2-side unpaired
t-test (with Welch’s correction) was performed on the data to determine signiﬁcant diﬀerences in protein levels between each un-coated and
coated CNTs. All these comparisons were signiﬁcant (p < 0.05), except where shown (ns: not signiﬁcant, p > 0.05).
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levels for Ox-CNTs and CMC-CNTs when bound to rhSP-D. The
mobilisation of the pro-inflammatory response was also indi-
cated in the up-regulation of NF-κB mRNA for Ox-CNTs
coated with rhSP-D, although the eﬀect seemed less pro-
nounced in CMC-CNTs with rhSP-D. No significant changes
were observed for NLRP3, suggesting that NLRP3 inflamma-
some activation was limited,34 as borne out by the 30% diﬀer-
ence in uptake between the CNTs with and without rhSP-D
coating (Fig. 4a).
Cytokine gene expressions of THP-1 cells were studied fol-
lowing treatment with rhSP-D coated CNTs, with or without
complement deposition. rhSP-D coated CMC-CNTs up-
regulated the pro-inflammatory cytokines (IL-1β and TNF-α) in
comparison to complement deposited rhSP-D coated
CMC-CNTs. However, we observed the opposite trend in the
case of IL-12 mRNA level (Fig. 6a). For anti-inflammatory cyto-
kines, unlike IL-10, TGF-β was slightly upregulated by com-
plement-deposited and rhSP-D coated CMC-CNTs. NLRP3 was
Fig. 6 (a) Cytokine gene expression proﬁle of diﬀerentiated THP-1 cells challenged with rhSP-D coated CMC-CNT with or without serum treat-
ment. rhSP-D bound CMC-CNTs were treated with or without serum. For the measurement of transcripts of pro-and anti-inﬂammatory cytokines as
well as NF-κB and NLRP3, cells were incubated with each CNTs, at the following four time-points: 30, 60, 120 and 360 minutes (X-axis). In control
experiments, cells were incubated with PBS only for 60 minutes. The expression of cytokines was measured using real-time qPCR and the data were
normalized to 18S rRNA gene expression as an endogenous control. Assays were conducted in triplicate. Error bars represent ±standard deviation.
A 2-way ANOVA was performed on the data to determine signiﬁcant diﬀerences in expression between rhSP-D coated CMC-CNT with or without
serum treatment. All these comparisons were signiﬁcant (p < 0.01). (b). Multiplex cytokine array analysis of supernatants of THP-1 cells treated with
rhSP-D bound CMC-CNT with or without serum. rhSP-D bound CMC-CNTs were incubated with diﬀerentiated THP-1 cells for 30 min, 1 h, 2 h, 6 h,
12 h, 24 h and 48 h. Cells from early time points (30 min, 1 h, 2 h, 6 h) were used for quantitative expression of diﬀerent cytokines at transcriptional
level. Culture supernatants from late time points (24 h and 48 h) were taken for measurement of protein level of secreted cytokines (IL-6, IL-10,
IL-12p40, IL-12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, IL-17A, IL-9, TNF-β), chemokines (MCP-3, MDC, eotaxin, fractalkine, GRO, IL-8, IP-10, MCP-1,
MIP-1α and MIP-1β), growth factors (IL-2, EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7 and VEGF), and other ligands and receptors (IFN-α2, IFN-
γ, FLT-3L, IL-1RA and sCD40L) by using a commercially available MagPix Milliplex kit (EMD Millipore). The X-axis shows the incubation periods; 24 h
and 48 h. Error bars represent ±standard deviation. A 2-way ANOVA was performed on the data to determine signiﬁcant diﬀerences in expression
between rhSP-D coated CNTs with or without serum treatment. All these comparisons were signiﬁcant (p < 0.05), except where shown (ns: not sig-
niﬁcant, p > 0.05).
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upregulated but NF-κB mRNA level was downregulated by
complement deposition on the rhSP-D coated CMC-CNTs.
Thus, complement deposition on CNTs dampened the pro-
inflammatory eﬀects of rhSP-D.
Complement deposition negates the pro-inflammatory
immune response induced by rhSP-D-coated CNTs
Since mRNA expression at early time points does not always
give all the clues about immune response over an extended
period, cytokine array analysis was performed on the super-
natants obtained at 48 h after treatment of U937 and at 24 h
and 48 h after treatment of THP-1 cells with CNTs (Fig. 5b and
6b). The data revealed a significant increase in the levels of
pro-inflammatory cytokines for CNTs coated with rhSP-D, as
indicated by IL-1α, IL-1β, TNF-α and IL-12p40. A similar profile
of chemoattractant was seen in IL-8, I-TAC, MIG and MCP-1,
indicating potential of rhSP-D to enhance inflammation.
There was also an increase in G-CSF levels, particularly in
CMC-CNTs coated with rhSP-D, suggesting a dampening of
fibrotic responses consistent with an increase in the inflam-
matory response.35 IL-10 levels were down-regulated by the
presence of rhSP-D coated on CMC-CNTs, whereas this was
slightly enhanced for rhSP-D coated Ox-CNTs. The diﬀerences
in protein levels between the un-coated CNT types were minor
except for IL-8, IL-1α, IL-10 and MCP-1, where there was a
marked enhancement of cytokine levels in CMC-CNTs com-
pared to Ox-CNTs. The opposite pattern of protein secretion
was observed for IL-1β and TNF-α, where they were suppressed
in CMC-CNTs compared to Ox-CNTs.
Like the U937 cells, the THP-1 cells produced an increased
pro-inflammatory response when challenged with rhSP-D-
coated CMC-CNTs (Fig. 6b). However, this eﬀect was consider-
ably reduced by complement deposition. Serum treatment of
rhSP-D-bound CMC-CNTs led to a dramatic downregulation of
IL-1β, TNF-α, IL-1α, IL-6, IL-8, MCP-1, MCP-3, MDC, GRO,
IP-10, MIP-1β, C-CSF, GM-CSF and VEGF. There was slight, but
significant down regulation in the levels of TNF-β, IL-17A,
IL-12, IL-9 and IL-15. Other targets in the analyte arrays such
as IL-10, IL-12p40, IFN-α2, eotaxin, fractalkine, MIP-1α, EGF,
FGF-2, IL-3, IL-7, FLT3L and soluble CD40L were not signifi-
cantly altered (Fig. 6b).
NF-κB nuclear translocation in response to rhSP-D coated
CMC-CNTs can be halted by complement deposition
THP-1 cells were used to investigate nuclear translocation of NF-
κB after CMC-CNT treatment using fluorescent staining tech-
niques. NF-κB, a transcription factor, is an important regulator
of expression of various pro-inflammatory cytokines induced in
response to external stimuli. Fig. 7 shows fluorescence in cells
exposed to CMC-CNTs for 2 h and stained with an antibody
against the p65 subunit of NF-κB. As shown in Fig. 7 in the
merged images, CMC-CNT exposure induced NF-κB nuclear
translocation compared to the control (cells only). This nuclear
translocation was more pronounced in the case of rhSPD-coated
CMC-CNTs. However, no translocation was observed for com-
plement deposited, rhSP-D-coated CMC-CNTs. This suggests
that the pro-inflammatory eﬀect observed for rhSP-D coated
CMC-CNTs was negated by serum deposition on rhSP-D coated
CMC-CNTs. This eﬀect is further evident in the downregulation
of TNF-α and IL-1β mRNA levels (Fig. 6a), and the secretion of
pro-inflammatory cytokines (TNF-α, IL-1β, IL-2 and IL-6), and
chemokines (IL-8, MCP-1, IP-10) (Fig. 6b).
Discussion
Carbon nanotubes (CNTs) have exceptional physical properties
that make them attractive and amenable for their exciting use
as therapeutic vehicles in the lungs.5,6,36,37 Thus, it is of great
importance to understand the biological interactions these
CNTs will have in the lungs, especially with innate immune
components, which are likely to be the first host defence
system to recognise these nanoparticles.3,38 Inevitably, use of
CNTs in the lungs will bring them into contact with pul-
monary surfactant, including hydrophilic surfactant proteins,
SP-A and SP-D, which are Ca2+-dependent pattern recognition
innate immune molecules.17
Fig. 7 Eﬀect of rhSP-D and/or complement deposition on CMC-CNT
on NF-κB cytoplasm to nucleus translocation. Diﬀerentiated THP-1 cells
were exposed to rhSP-D bound CMC-CNTs (rhSP-D + CMC-CNT),
rhSP-D bound CMC-CNT with complement deposition (rhSP-D + serum
+ CMC-CNT), complement deposited CMC-CNTs (serum +
CMC-CNTs), or CMC-CNT alone for 2 h. Cells were washed, ﬁxed, per-
meabilised and incubated with rabbit anti-NF-κB p65 antibodies, fol-
lowed by Alexa Fluor 488-goat anti rabbit antibody (green). The nucleus
was stained with Hoechst 33342 (blue). Scale bar 20 μm. Arrows high-
light nuclear NF-κB in the merged images.
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Of the two hydrophilic surfactant proteins, SP-D has been
shown to mount a strong pro-inflammatory response when
engaging with a variety of pathogens.39,40 Its structure includes
a multimerising cysteine-containing N-terminal region, a
triple-helical collagen-like region, a trimerising α-helical
coiled-coil neck region, followed by a C-terminal C-type lectin
or carbohydrate recognition domain (CRD). The primary
subunit of three polypeptide chains is tetramerised, and can
polymerise further to form fuzzy ball-like dodecamers.17 In
this study, we have used recombinant human SP-D expressed
in E. coli, which consists of three CRDs, a neck and eight gly-
Xaa-Yaa collagen region repeats, where Xaa and Yaa could be
any amino acid. The C-terminal homotrimeric CRD region is
the principal ligand-binding domain of SP-D that recognises
carbohydrate and/or charge patterns on pathogens, allergens,
receptors/binding proteins, and apoptotic cells.41 This ligand
binding causes opsonic eﬀects, leading to enhanced phago-
cytosis and clearance mechanisms via superoxidative burst
and mostly pro-inflammatory immune response by phagocytic
cells.42 In vivo models of allergy43–45 and SP-D knock-out
mice studies have revealed that SP-D can modulate adaptive
immune responses further downstream from its eﬀector func-
tions that can include helper T cell polarisation43 and apopto-
sis induction in immune-activated cells.31,46,47 Thus, inter-
action between SP-D and nanoparticles can have profound and
wide-ranging impact on the pulmonary innate and adaptive
immune mechanisms.
Both SP-A and SP-D have been shown to interact with nano-
particles and alter their phagocytosis. Metal oxide nano-
particles can bind SP-A purified from bronchoalveolar lavage,
depending on their surface chemistry.48 Enhanced uptake of
nanoparticles by alveolar macrophages has been reported by
SP-A, which prefers hydrophobic coating, whilst SP-D prefers
hydrophilic surface on the nanoparticles.49,50 Decreased
uptake of nanoparticles has also been shown in alveolar
macrophages and lung dendritic cells isolated from SP-D
knockout mice, when compared to wild type mice.25
In the present study, we set out to examine the eﬀect of
rhSP-D binding to the surface of functionalised CNTs (Ox-CNT
and CMC-CNTs) on their uptake by macrophage cell lines.
THP-1 cells constitutively express complement receptor
3 (CR3) whose surface expression is further up-regulated by
PMA treatment.51 The observed enhanced uptake of rhSP-D
coated CMC-CNTs could be thus CR3 mediated, as observed
for SP-A.52 We also tested if rhSP-D coated CNTs continue to
activate the complement classical pathway, exploring the possi-
bility of independent and multiple interactions of key innate
immune molecules with CNTs. It has been shown previously
that serum treatment (i.e. complement deposition) enhances
CNT uptake by macrophages (U937), B cells (Raji),4 and
human bronchial epithelial cells.52
We have previously shown that complement deposition
occurs on CNTs, mainly via the classical pathway, which
enhances their uptake by complement receptors on macro-
phages and B cells, whilst down-regulating the pro-inflamma-
tory cytokine response via the up-regulation of IL-10.4,28 We
have also shown that C1q, the first recognition subcomponent
of the classical pathway, binds to CNTs via its ligand recognis-
ing globular (gC1q) domain, as revealed by the use of recombi-
nant globular head modules (ghA, ghB and ghC).3,4 It is likely
that the binding of C1q to CNTs is through the recognition of
charge patterns.3,4,53,54 SP-D is of similar structure to C1q but
is a mainly carbohydrate or charge pattern recognition mole-
cule, perhaps recognising vicinal diol groups as does
mannose-binding lectin.19 Thus, in addition to the modulatory
properties of rhSP-D after binding to CNTs, we also examined
the eﬀect of rhSP-D bound to CNTs on complement activation.
Interestingly, complement consumption was enhanced 2-fold
by rhSP-D when it was bound to Ox-CNTs as well as
CMC-CNTs. These observations indicate that SP-D binds
diﬀerent sites than C1q on CNTs, and thus does not inhibit
binding of C1q to CNTs. Increased complement activation by
rhSP-D coated CNTs is most likely caused by bound rhSP-D
forming additional binding sites for C4b and C3b. In contrast,
the recombinant ghA, ghB and ghC modules, bound to CNTs,
have been shown to inhibit classical pathway activation.3,4
This is because they do compete with C1q for binding to the
CNTs.
We also examined the downstream cytokine response from
macrophage cell lines treated with CNTs with and without
rhSP-D coating. rhSP-D bound CNTs up-regulated the pro-
inflammatory response in U937 and THP-1 cells. It is also
likely that the majority of rhSP-D coated CNTs interact with
Toll-like receptor 4 (TLR4), and thus initiate the IL-1β pathway
release via NLRP3 inflammasome activation.34 The up-regu-
lation of IL-12 may indicate Th1 cell polarisation,55 suggesting
that SP-D switches from eliciting a Th2 to a Th1 response
during interaction with CNTs. These reports are consistent
with an earlier report.4 rhSP-D coating on both types of CNTs
was also found to up-regulate G-CSF and I-TAC, which are
important for the mobilisation of neutrophils and T cells,
respectively. This further illustrates the potential of rhSP-D to
cause inflammatory response in conjunction with CNTs.
IL-1α and IL-1β are prototypical inflammatory cytokines,
which can additionally induce endothelial cells to produce
infiltration-causing MCP-1.56 In addition, IL-1 also induces
IFN-γ production by Th1 and NK cells via IL-12 secretion by
antigen presenting cells.57 In addition, IL-1 causes matrix
metalloproteinases production by resident fibroblasts causing
extracellular matrix degradation. Thus, suppression of these
cytokines, whose generation involves inflammasomes and
TLR4, is beneficial for pulmonary homeostasis. It is curious
that IL-1 itself can upregulate the pyrogenic and acute phase
protein TNF-α in addition to perhaps TLR4 mediated inter-
action involving SP-D and CNT.58
One crucial observation being reported here is the up-regu-
lation of VEGF by rhSP-D bound CNTs. VEGF is known to
increase edema (vascular permeability) in asthma, involving
Th2 dependent allergen sensitisation and pulmonary inflam-
mation.59 It is quite clear that CNT-bound rhSP-D does the
opposite of soluble rhSP-D in murine models;43 however this
eﬀect can be overcome by complement deposition. A similar
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role can be attributed in Th2-dependent lung diseases. IL-8, as
a crucial neutrophil chemoattractant, has been shown to be
involved in acute lung injury.60 NF-κB nuclear translocation
induced by nanoparticles has been previously shown in
human kidney cells.61 Similarly, both in vivo and in vitro
studies have shown activation of NF-κB and production of pro-
inflammatory mediators such as TNF-α, IL-1β, IL-8 and IL-6 by
metallic nanoparticles62 and single-walled CNTs.63
The results presented here raise several important issues.
Functionalized CNTs, as a charge pattern recognition target,
can be recognised by SP-D and C1q simultaneously. This study
is one of few which we have published, in which the binding
of several other proteins, e.g. human serum albumin (HSA),
bovine serum albumin (BSA), fibrinogen, human C1q, recom-
binant fragments of C1q, and SP-A, have been
studied.3,4,19,20,28,33 It has been shown that coating CNTs with
other proteins such as BSA and fibrinogen can enhance comp-
lement activation.28 However, the binding of SP-D from the
lung surfactant fluid to CNTs is highly selective, and therefore,
SP-D binding to CNT in the lung will occur more avidly than
the binding of other proteins. Thus, in the context of lungs,
the eﬀects of SP-D will dominate the eﬀect of other proteins.
In addition, we have also carried out control experiments
using maltose-binding protein (MBP), which did not modify
the eﬀect of CNTs on immune cells.
SP-D opsonisation, similar to complement deposition,
leads to enhanced uptake of CNTs by macrophages. However,
both opsonins (SP-D and complement), when together, restrict
the entry of the CNTs into macrophages. The ability of com-
plement to suppress pro-inflammatory response by rhSP-D
bound CNTs makes a good argument for coating of CNTs with
small fragments of recombinant complement components for
therapeutic applications.
In the context of the lungs, the use of therapeutic CNTs
needs to be carefully considered, since their interaction with
SP-D could cause harmful inflammation analogous to what
has been observed with asbestos.64,65 Furthermore, it has been
reported that carbon black particles have the ability to comple-
tely sequester SP-D from suspension.66 Sequestration of surfac-
tant proteins aggravated ongoing Streptococcus penumoniae
infection in rats exposed to airborne particles of sizes less
than 10 µm.67 Furthermore, sequestration of SP-D and SP-A by
nanoparticles was shown to alter the ability of these proteins
to neutralise influenza A infection in vitro.27 Immobilization of
these innate immune molecules by nanoparticles could thus
make the host susceptible to viral and bacterial infection.
Modified CNTs intended for administration to the lung should
therefore be examined for their interaction with SP-D.
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